CFD Guided Optimization of Nose-to-Lung Aerosol Delivery in Adults: Effects of Inhalation Waveforms and Synchronized Aerosol Delivery

Dutta, Rabijit; Spence, Benjamin; Wei, Xiangyin; Dhapare, Sneha; Hindle, Michael; Longest, P. Worth

doi:10.1007/s11095-020-02923-8

Cited by 22 publications

(9 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They constructed the nasal cavity and HRT model by using CT-scan data. Bass et al [38] and Dutta et al [39] used complete pulmonary model connecting NMT to the HRT to predict the deposition and distribution of the drug taken from nasal route. Some researchers reported that with the help of CFD laced with optimization techniques, the efficiency of nasal inhalers can be improved [40].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Challenges in Drug Delivery Through Intranasal Route: A CFD Perspective

Tiwari¹,

Paul²,

Jain³

2022

Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022)

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, Dutta et al [39] constructed an adult NMT model connected with a thirdgeneration human airways with a nasal inhaler. They adopted the polyhedral mesh, used LRN k-ω turbulence modelfor transitional and turbulent flows.…”

Section: Cfd Findingsmentioning

confidence: 99%

Challenges in Drug Delivery Through Intranasal Route: A CFD Perspective

Tiwari¹,

Paul²,

Jain³

2022

Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022)

View full text Add to dashboard Cite

show abstract

“…Notwithstanding this appreciable properties, the therapeutic use of N/OFQ is strongly compromised due to its low water solubility related to its peptide nature [ 13 , 14 , 15 ]. In fact, reduced protein stability during aerosolization and the pulmonary microenvironment represent major obstacles to its pulmonary administration [ 16 , 17 , 18 ]. This has spurred the development of selective NOP receptor agonists, including non-peptide molecules [ 6 , 19 ] and carrier systems for N/OFQ improving the therapeutic efficacy [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness

et al. 2022

View full text Add to dashboard Cite

Asthma is characterized by chronic inflammation and a variable degree of airway hyperresponsiveness (AHR). Our previous papers documented a role for Nociceptin/Orphanin FQ (N/OFQ) and its receptor N/OFQ peptide (NOP) in AHR. Therefore, the aim of this study was to improve the bioavailability of N/OFQ by developing solid lipid nanoparticles (SLNs). N/OFQ-loaded SLNs were prepared by the Quasi Emulsion Solvent Diffusion (QESD) technique and then characterized. Brown Norway rats were sensitized to ovalbumin (OVA) and treated with an intratracheal administration of saline solution or N/OFQ-SLN. Then, 24 h after the last challenge, functional histological and molecular evaluations were performed. SLNs showed a mean diameter of 233 ± 0.03 nm, a polydispersity index (PDI) value around 0.28 ± 0.02 and a drug release percentage of 84.3. The in vitro release of N/OFQ from SLNs showed that the release of the peptide starts already after two hours of incubation. Animals receiving N/OFQ-SLN showed a significative decrease in allergen-induced AHR compared to the control group. These results showed the positive effects of N/OFQ-SLNs on the inflammatory process and on the mechanical properties of the airways, suggesting that the innovative nanotechnological approach may be therapeutically beneficial for asthmatic patients.

show abstract

“…Both drug formulation (in suspension or solution base) and proper device design are essential for the effective treatment of respiratory conditions. Since drug deposition is unevenly distributed within the lungs [6,7], drug delivery must be better targeted to generate and deliver fine aerosols into the lungs [8].…”

Section: Introductionmentioning

confidence: 99%

A CFD Investigation on the Aerosol Drug Delivery in the Mouth–Throat Airway Using a Pressurized Metered-Dose Inhaler Device

et al. 2022

View full text Add to dashboard Cite

Inhalation therapy involving a pressurized metered-dose inhaler (pMDI) is one of the most commonly used and effective treatment methods for patients with asthma. The purpose of this study was to develop a computational fluid dynamics (CFD) model to characterize aerosol flow issued from a pMDI into a simulated mouth–throat geometry. The effects of air flow rate and cone angle were analyzed in detail. The behaviour of the multiphase flow initiated at the inhaler actuation nozzle and extended through the mouth–throat airway was simulated based on the Eulerian-Lagrangian discrete phase model, with the k-ω model applied for turbulency. We validated our model against published experimental measurements and cover the hydrodynamic aspect of the study. The recirculation we observed at the 90° bend inside the mouth–throat airway resulted in the selective retention of larger diameter particles, and the fluid flow patterns were correlated with drug deposition behaviour. Enhancing air flow rates up to three times reduced the aerodynamic particle diameters to 20%. We also observed that, as cone angle increased, mouth deposition increased; an 8° cone angle was the best angle for the lowest mouth–throat deposition.

show abstract

CFD Guided Optimization of Nose-to-Lung Aerosol Delivery in Adults: Effects of Inhalation Waveforms and Synchronized Aerosol Delivery

Cited by 22 publications

References 67 publications

Challenges in Drug Delivery Through Intranasal Route: A CFD Perspective

Challenges in Drug Delivery Through Intranasal Route: A CFD Perspective

Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness

A CFD Investigation on the Aerosol Drug Delivery in the Mouth–Throat Airway Using a Pressurized Metered-Dose Inhaler Device

Contact Info

Product

Resources

About